𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oral budesonide therapy improves quality of life in patients with collagenous colitis

✍ Scribed by Ahmed Madisch; Peter Heymer; Claudia Voss; Bernd Wigginghaus; Elke Bästlein; Ekkehard Bayerdörffer; Eberhard Meier; Wolfgang Schimming; Birgit Bethke; Manfred Stolte; Stephan Miehlke

Publisher
Springer
Year
2004
Tongue
English
Weight
136 KB
Volume
20
Category
Article
ISSN
0179-1958

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Budesonide treatment of patients with co
Budesonide treatment of patients with collagenous colitis restores normal eosinophil and T-cell activity in the colon
✍ Michael Wagner; Maria Lampinen; Per Sangfelt; Margret Agnarsdottir; Marie Carlso 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 495 KB

## Background: The aim of this study was to assess the activity of eosinophils, neutrophils, and CD4þ as well as CD8þ T-cells in 11 patients with active collagenous colitis (CC) before and after 8 weeks of budesonide treatment (9 mg once daily) compared to 10 healthy individuals. Methods: Clinica

Epoetin alfa improves quality of life in
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy
✍ Paul J. Pockros; Mitchell L. Shiffman; Eugene R. Schiff; Mark S. Sulkowski; Zoba 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

Anemia and decreased health-related quality of life (HRQL) are common in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. In a randomized, prospective study evaluating the effectiveness of epoetin alfa in maintaining R

Rasagiline improves quality of life in p
Rasagiline improves quality of life in patients with early Parkinson's disease
✍ Kevin M. Biglan; Steven Schwid; Shirley Eberly; Karen Blindauer; Stanley Fahn; T 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 1 views

The objective of this study was to determine the effects of rasagiline as monotherapy on quality of life (QOL) in patients with early Parkinson's disease (PD). Rasagiline, a potent, second-generation, irreversible, selective monoamine oxidase B inhibitor improves PD symptoms in patients with early P